February 2, 2016
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on February 1 recommended approval for Novartis Pharma’s malignant melanoma drugs dabrafenib and trametinib. The Pharmaceutical Affairs and Food Sanitation Council’s Second Committee on Drugs supported the...read more